<DOC>
	<DOC>NCT01530529</DOC>
	<brief_summary>The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects. Two doses of the modified-release formulation and one dose of the immediate-release formulation will be evaluated under fasted conditions. One dose of the modified-release formulation will also be evaluated in the presence of food.</brief_summary>
	<brief_title>A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999</brief_title>
	<detailed_description />
	<criteria>Male or female of nonchildbearing potential Evidence of clinicallysignificant medical illness, history of seizures, any condition possibly affecting drug absorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>PF-05180999</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Schizophrenia and Disorders with Psychotic Features</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>